StocksMedium•13 November 2026•
1 min read
DiaSorin Q3 Revenue Rises 9.8% as Company Reaffirms 2026 Outlook
Key Facts
1DiaSorin reported Q3 revenue of €308 million, marking a 9.8% increase year-over-year.
2Adjusted EBITDA reached €103 million, representing 34% of revenues at constant exchange rates.
3The company reaffirmed its FY2026 outlook, expecting revenue growth of 5-6% and an adjusted EBITDA margin of 32-33%.
DiaSorin reported Q3 2026 revenue of €308 million, marking a 9.8% increase compared to the same period last year. Seeking Alpha reported that adjusted EBITDA reached €103 million, representing 34% of revenues at constant exchange rates.
The company reaffirmed its full-year 2026 outlook, expecting revenue growth between 5% and 6%. DiaSorin also maintains its target for an adjusted EBITDA margin of 32% to 33%, highlighting operational stability within the healthcare diagnostics sector.